vaccine for the novel coronavirus. The company has entered an exclusive licence agreement to develop, commercialise and manufacture UB-612, the first multitope peptide-based vaccine to fight COVID-19, for India and UNICEF, Aurobindo Pharma said in a regulatory filing.“We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic.